[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.127.188. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Correspondence
February 1, 2008

Severe Purpuric Xerotic Dermatitis Associated With Gefitinib Therapy

Arch Dermatol. 2008;144(2):269-270. doi:10.1001/archdermatol.2007.53

Gefitinib (Iressa; AstraZeneca, London, England) has been used in the treatment of non–small cell lung cancer (NSCLC).1 The cutaneous toxic effects associated with epidermal growth factor receptor (EGFR) inhibitors are follicular eruption, paronychia, and xerosis.24 Herein, we describe 3 patients with reticular erythematous eruptions on the lower extremities associated with gefitinib.

First Page Preview View Large
First page PDF preview
First page PDF preview
×